Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.96.73 CHF
Change Today -0.70 / -0.72%
Volume 100.0K
NOVNEE On Other Exchanges
Symbol
Exchange
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
SIX Swiss Ex
Frankfurt
As of 10:43 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by NOVARTIS AG-2ND LINE (NOVNEE) in the last 6 months

Announced 03/30/15
25.00M for Aduro BioTech, Inc.
Private Placement

Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,


NOVNEE's price was unchanged after the transaction was announced on 03/30/15.
Investor / Buyer
Novartis AG
 
Announced 03/13/15
Valneva SE
Merger/Acquisition

GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.


NOVNEE's price was unchanged after the transaction was announced on 03/13/15.
Investor / Buyer
GlaxoSmithKline plc
Creditor / Lender
Novartis AG
 
Announced 01/7/15
11.00M for Caribou Biosciences, Inc.
Private Placement

Caribou Biosciences, Inc. announced that it has received undisclosed amount in series A round of equity funding from Novartis AG on January 7, 2015.


NOVNEE's price was unchanged after the transaction was announced on 01/7/15.
Investor / Buyer
5 Prime Ventures
Fidelity Biosciences
Mission Bay Capital LLC
Novartis AG
 
Announced 11/18/14
15.00M for Intellia Therapeutics Inc.
Private Placement

Intellia Therapeutics announced that it has received $15 million in its first round of funding from new investors Atlas Venture L.P. and the research arm of Novartis AG. on November 18, 2014. Atlas Venture L.P. invested in the formation of the company.


NOVNEE's price was unchanged after the transaction was announced on 11/18/14.
Investor / Buyer
Atlas Venture L.P.
Novartis AG
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVNEE:SW SFr.96.73 CHF -0.70

NOVNEE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $105.01 USD +4.50
Johnson & Johnson $100.13 USD +0.93
Merck & Co Inc $59.86 USD +0.30
Pfizer Inc $34.08 USD +0.15
Roche Holding AG SFr.269.40 CHF +1.00
View Industry Companies
 

Industry Analysis

NOVNEE

Industry Average

Valuation NOVNEE Industry Range
Price/Earnings 24.2x
Price/Sales 4.7x
Price/Book 3.3x
Price/Cash Flow 13.8x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-2ND LINE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.